Insulin receptor (IR) and the type I IGF receptor (IGF1R) are structurally and functionally related. The function of IGF1R in cancer has been well documented and anti-IGF1R strategies to treat cancer have shown initial positive results. However, the role of IR in tumor biology, independent of IGF1R, is less clear. To address this issue, short hairpin RNA (shRNA) was used to specifically downregulate IR in two cancer cell lines, LCC6 and T47D. Cells with reduced IR showed reduced insulinstimulated Akt activation, without affecting IGF1R activation. Cells with reduced IR formed fewer colonies in anchorage-independent conditions. LCC6 IR shRNA xenograft tumors in mice had reduced growth, angiogenesis and lymphangiogensis when compared with LCC6 wild-type cells. Accordingly, LCC6 IR shRNA clones produced less hypoxia-inducible factor-1a, vascular endothelial growth factor (VEGF)-A and VEGF-D. Furthermore, LCC6 IR shRNA cells formed fewer pulmonary metastases when compared with LCC6 wild-type cells. Using in vivo luciferase imaging, we have shown that LCC6 IR shRNA cells have less seeding and colonization potential in the lung and liver of mice than LCC6 cells. In conclusion, downregulation of IR inhibited cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis. Our data argue that IR should also be targeted in cancer therapy.
Introduction
The insulin-like growth factor (IGF)/insulin system is complex, including three ligands (insulin, IGF-I and IGF-II) and at least four receptors (insulin receptor (IR), the type I IGF receptor (IGF1R), hybrid IR/ IGF1R receptor and the type II IGF receptor). Owing to differential mRNA splicing, two IR isoforms exist, IR-A and IR-B. Although type II IGF receptor does not possess kinase activity, both IGF1R and IR contain kinase domains in the b-subunits. Activated receptor, by ligand binding, recruits adaptor molecules, such as insulin receptor substrates 1 and 2 (IRS-1 and IRS-2), resulting in the activation of multiple downstream signaling pathways, including the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathway and the phosphatidylinositol 3-kinase pathway (Sachdev and Yee, 2001; Zhang and Yee, 2006) .
In this complex system, IGF1R and IR interact in several important ways. First, IR and IGF1R share high homology within their kinase domains, and tyrosine kinase inhibitors (TKIs) have not yet been developed that can distinguish between them. Second, IGF1R and IR form hybrid receptors by hetero-tetramerization (Kasuya et al., 1993) . Third, whereas insulin binds to IR and IGF-I binds to IGF1R and the hybrid receptor, IGF-II binds to IGF1R, the hybrid receptor, and one of the IR splice isoforms, IR-A. Finally, IGF1R, IR and the hybrid receptor share similar downstream signaling adaptor molecules, such as IRS-1 and IRS-2, and signaling pathways, including mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
IGF1R has been shown to have a critical role in cancer and several anti-IGF1R antibodies are currently in clinical trials for various types of solid tumors (Sachdev and Yee, 2006; Weroha and Haluska, 2008; Hewish et al., 2009) . Unlike other targeted therapies, the clinical development of anti-IGF1R antibodies is further along than the TKIs (Weroha and Haluska, 2008; Hewish et al., 2009) . There is concern that inhibition of IR by TKIs might affect glucose homeostasis and have undesirable toxicity.
The potential benefit of inhibiting IR in cancer has not been shown well. In fact, recent studies on the function of insulin and the IR in cancer biology have been relatively sparse (recently reviewed by Frasca et al., 2008; Pollak, 2008) . It is notable that a role for insulin was first shown in the 1970s. Physiologic concentrations of insulin stimulated proliferation of breast cancer cells, whereas insulin deprivation inhibited breast cancer proliferation in a rat model (Heuson and Legros, 1972; Osborne et al., 1976) . Later studies have shown that MCF-7 breast cancer cells did not form tumors in a mouse model of insulin deficiency (Nandi et al., 1995) . Furthermore, IR, especially the fetal IR-A isoform, is highly expressed in breast cancer and other malignancies (Frasca et al., 2003; Zhang et al., 2007; Avnet et al., 2009) . Recently, it was shown that IR downregulation inhibits PyVmT (polyoma virus middle T antigen) -induced tumor growth in vivo (Novosyadlyy et al., 2009) . In addition to these laboratory studies, epidemiological studies suggest that patients with hyperinsulinemia have a worse cancer outcome (Goodwin et al., 2002; Ma et al., 2008) . Despite these data implicating IR in tumorigenesis, the effect of inhibiting IR alone on cancer cell biology has not been well characterized.
In this study, we specifically downregulated the level of IR in two cancer cell lines without affecting the level or activity of IGF1R. Our data show that downregulation of IR inhibited cancer cell proliferation, angiogenesis and lymphangiogenesis. More importantly, we show that downregulation of IR inhibited cancer metastasis in an athymic mouse model, even in the presence of functional IGF1R. Our data strongly argue that the IR should also be targeted in cancer therapy.
Results

IR shRNA clones had diminished IR level
To assess the function of the IR in cancer biology, we used short hairpin RNA (shRNA) technology to specifically downregulate IR levels in two cancer cell lines, LCC6 and T47D. LCC6 is a highly metastatic derivative cell line of MDA-MB-435 (Leonessa et al., 1996) . A soluble truncated IGF1R inhibits metastasis of MDA-MB-435 cells (Dunn et al., 1998) . Previous studies in our laboratory have shown that, in LCC6 cells, inhibition of the IGF signaling pathway by a dominantnegative form of IGF1R does not affect cell proliferation, but inhibits the ability of the cells to metastasize to the lung of athymic mice (Sachdev et al., 2004) . T47D, a breast cancer cell line, has been reported to proliferate in response to insulin (Karey and Sirbasku, 1988) . In LCC6 cells, two IR shRNA clones, IR6 and IR14, were selected. Both clones had approximately 71% IR downregulation, as measured using flow cytometry (Figure 1a) . One IR shRNA clone, IR12, was also selected in T47D cells (Figure 1b ). The T47D clone had approximately 66% IR downregulation.
IR shRNA clones had diminished phosphorylation of Akt at Ser 473 in response to insulin To examine the signaling profiles of LCC6 and IR shRNA clones, cellular lysates before and after insulin treatment were analyzed using a human phosphorkinase array. This assay allowed simultaneous detection of the relative levels of 46 phosphorylation sites from key proteins involved in cell proliferation and meta- (Figure 2a) . Therefore, the major phosphorylation event that was altered by IR downregulation was that of Akt, a key mediator in the phosphatidylinositol 3-kinase pathway. We further verified this signaling difference using immunoblotting. As shown in Figure 2b , insulin and IGF-I treatment resulted in enhanced Ser 473 phosphorylation and activation of Akt in LCC6 cells. In contrast, IR6 or IR14 cells, which had a diminished level of IR, failed to respond to insulin, as measured by the activation of Akt. IR6 and IR14 cells had intact IGF1R levels; therefore, they responded to IGF-I similar to the wild-type cells. In addition, the constitutive activation of ERK1/2 and RSK were confirmed using their phosphospecific antibodies. It is noteworthy that a pRS vector clone has similar signaling activation to wild-type LCC6 ( Supplementary Figure 1) , excluding the possibility that transfection and clonal selection by puromycin substantially affected cell signaling in our settings. T47D is a less aggressive cell line, and both Akt and ERK1/2 activation are regulated by IGF-I and insulin (Byron et al., 2006) . As shown in Figure 2c , in response to insulin, IR12 cells have diminished activation of IRS1/2, Akt and ERK1/2 compared with pRS vector control cells. These data suggest that downregulation of IR affected insulin signaling and decreased the phosphorylation of Akt Ser 473, whereas IGF-I signaling remained intact.
IR shRNA clones formed smaller colonies than wild-type cells in vitro Consistent with the literature, T47D cells proliferated in response to insulin in a monolayer growth assay (Figure 3a) . IR downregulation significantly decreased insulin-stimulated growth. In contrast, IGF-stimulated growth was largely unchanged in the IR clone. Furthermore, IR12 cells formed fewer and smaller colonies than T47D wild-type and the vector control cells, as measured using soft agar assay (Figure 3b ).
We and others have previously shown that LCC6 cells do not respond to either IGF-I or insulin in monolayer growth assays (Sachdev et al., 2004) . Consistent with that observation, LCC6 IR6 and IR14 clones had a monolayer growth pattern similar to LCC6 wild type IR6 and IR14 cells (b) or T47D pRS and IR12 cells (c) were serum starved overnight, and then treated with or without 20 nM insulin, or 5 nM IGF-I for 10 min. Cellular lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the phosphorylation levels of Akt at Ser473, ERK1/2 (MAPK) at Thr202/Tyr204, RSK at Ser380 and protein levels were assessed using specific antibodies by immunoblotting.
Insulin receptor affects cancer proliferation and metastasis H Zhang et al (data not shown). However, both IR shRNA clones formed fewer colonies than LCC6 cells and vector control cells in an anchorage-independent manner ( Figure 3c ). This is consistent with our finding that insulin increased colony formation of LCC6 (data not shown).
IR shRNA clones formed smaller xenograft tumors than LCC6
To determine whether downregulation of IR inhibits tumor growth, LCC6 and the two shRNA clones were injected into the mammary fat pad of athymic mice. All cells formed xenograft tumors in athymic mice. However, IR6 and IR14 xenografts grew significantly slower than that of LCC6 cells (Figure 4a ). At the end of the experiments (28 days of tumor growth), tumor sections were analyzed using Ki-67 and TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining. As shown in Figures 4b and c, LCC6 tumors had a significantly higher proliferation rate than IR6 and IR14 tumors as measured by percentage of Ki-67 staining cells. In addition, TUNEL staining of tumor sections revealed that there was a large amount of apoptosis/necrosis in the center of LCC6 tumor sections, whereas the apoptosis/necrosis rate in the IR6 and IR14 tumors was much less (Figure 4d ). These data indicate that LCC6 tumors were highly proliferative and highly Insulin receptor affects cancer proliferation and metastasis H Zhang et al apoptotic/necrotic, and thus had a higher turnover rate than IR6 and IR14 tumors.
IR shRNA xenografts had reduced angiogenesis and lymphangiogenesis in athymic mice
To assess the angiogenic and lymphangiogenic potential of LCC6 and IR shRNA xenografts, LCC6, pRS vector cells and IR shRNA clones were injected into the mammary fat pad of athymic mice to form xenograft tumors (Figure 5a ). Mice were killed earlier (at day 21 of tumor growth) to examine the early development of blood vessels and lymphatic vessels in xenograft tumors. Frozen tumor sections were analyzed for the expression of CD31 and lymphatic vessel endothelial hyaluronan receptor 1, which are cell markers of blood and lymphatic vessels, respectively. As shown in Figure 5b , LCC6 or pRS vector xenografts had very well-developed lymphatic vessels and blood vessels around the tumor periphery. The LCC6 wild-type tumors did not contain lymphatic vessels, but contained very dense blood vessels within the tumor. In contrast, IR shRNA clone xenografts had very poor lymphatic and blood vessel development around the tumor periphery, and they contained poorly developed blood vessels in the tumor interior. These data suggest that downregulation of IR inhibits angiogenesis and lymphangiogenesis of xenograft tumors.
IR shRNA clones had less VEGF-A and VEGF-D production than LCC6 cells
The reduced angiogenesis and lymphangiogenesis in IR shRNA xenograft tumors led us to analyze whether these cells produced less angiogenic factors, such as vascular endothelial growth factor (VEGF)-A, and lymphangiogenic factors, such as VEGF-C and VEGF-D. As shown in Figure 6a , in response to insulin, hypoxia-inducible factor-1a (an upstream regulator of VEGF-A expression), VEGF-A and VEGF-D mRNA levels were significantly upregulated in LCC6 wild-type cells. However, insulin failed to induce changes in hypoxia-inducible factor-1a, VEGF-A and VEGF-D mRNA levels in IR6 and IR14 clones. VEGF-C was at undetectable levels in this cell line (data not shown). Accordingly, we measured the level of VEGF-A in conditioned media of cultured cells ( Figure 6b ). LCC6 had basal VEGF-A production, and VEGF-A levels were increased in serum conditions. Its production was further enhanced in a condition that mimics hypoxia by addition of cobalt chloride and 2% fetal bovine serum (FBS). IR6 and IR14 cells produced a significantly lower amount of VEGF-A than LCC6 cells.
IR shRNA clones had diminished lung metastasis
It has previously been reported that LCC6 xenografts spontaneously metastasize to the lungs of athymic mice after orthotopic injection (Price, 1996; Sachdev et al., 2004) . Mice with LCC6, IR6 or IR14 xenografts were killed on the same day of tumor growth (28 days), lungs were harvested and lung sections were examined for cancer cell micrometastasis. All mice (5/5) with LCC6 xenograft tumors had numerous lung micrometastases, whereas 0/5 mice with IR6 or IR14 xenografts had micrometastasis, when animals were killed at the same time point (data not shown). However, in this experiment, LCC6 xenografts were much larger than those of (a) 5 Â 10 6 LCC6, pRS vector cells and IR shRNA clones were injected into the mammary fat pad. Tumor growth was measured twice a week and is shown as tumor volume. Mice were killed after 21 days of growth. One-way analysis of variance (ANOVA) analysis was performed to compare the tumor growth within the same day. *Po0.0001. (b) Tumors were frozen in optimal cutting temperature (OCT) solution. Tumor sections were stained with lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) antibody, followed by a Cy2-conjugated secondary antibody and phycoerythrin (PE)-conjugated CD31 antibody. Finally, the sections were stained for the nucleus with 4,6-diamidino-2-phenylindole (DAPI). Confocal microscopy was performed and representative images of tumor periphery and tumor interiors are shown. The white dashed lines indicate the tumor boundary. Blue: DAPI; Green: LYVE-1; Red: CD31 (the yellow color is an overlay of red and green). Scale bar ¼ 50 mm.
Insulin receptor affects cancer proliferation and metastasis H Zhang et al IR6 or IR14, which provided more potential seeding cells for lung metastasis. To rule out the possibility that fewer lung metastases were due to the diminished number of cells in the IR shRNA tumors, mice carrying xenografts of LCC6, IR6 or IR14 were killed on different days when tumors reached approximate equal volume (B1000 mm 3 ), and lung micrometastases were examined. As shown in Figures 7a and b , all mice (5/5) with LCC6 xenografts showed numerous lung micrometastasis, whereas only 1/5 mice with IR6 xenografts and 2/5 mice with IR14 xenografts showed small numbers of lung micrometastasis. These data suggest that downregulation of IR attenuated cancer cell micrometastasis in the lung.
IR shRNA clones had less seeding and colonization potential in distant organs than LCC6 cells To assess the seeding and growth potential of IR shRNA clones compared with LCC6 cells, luciferase- shRNA clones were serum starved overnight, and then treated with or without 20 nM of insulin for 24 h. Total RNA was isolated and gene expression profiles were analyzed using real-time RT-PCRs. mRNA levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels. IR mRNA levels were used as a positive control for RT-PCR analysis. One-way analysis of variance (ANOVA) analysis was performed to compare the statistical significance among different cell lines. An unpaired t-test was used to compare the difference between two treatment conditions. *Po0.05; **Po0.01. (b) LCC6 cells and IR shRNA clones were incubated in different conditions as indicated for 48 h. VEGF-A production in condition media was quantified using enzyme-linked immunosorbent assay (ELISA). One-way ANOVA analysis was performed to compare the difference within the same treatment group. **Po0.001.
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H Zhang et al expressing LCC6 and IR shRNA clones were created. in vitro assays confirmed that these three cell lines expressed similar amounts of luciferase (data not shown). Equal numbers of LCC6, IR6 or IR14 cells carrying luciferase were injected into the tail vein of athymic mice. The successful delivery of the cells was confirmed using luminescent imaging after 3 h of injection ( Figure 8a , first row). Mice were examined by luminescent imaging once a week. LCC6 cells developed lung metastasis as early as 14 days after injection. At day 51, mice were first imaged alive and then killed to harvest tissues. The lungs and livers of the mice were imaged (Figure 8b ). In the group of mice with LCC6 injection, 5/5 mice had lung metastasis and 3/5 mice had liver metastasis. None of the four mice injected with IR6 cells had lung or liver metastasis; in mice injected with IR14 cells, 1/5 mice had a small lung metastasis and 0/5 mice had liver metastasis. In one mouse with IR6 injection, we detected two regional metastases by wholeanimal imaging, but neither metastasis was detected in the lung or liver imaging, suggesting that they may be lymph nodes or bone metastasis. Overall, our data suggest that downregulation of IR in cancer cells inhibited their ability to seed and colonize in distant organs.
Discussion
Because the function of IGF1R in cancer biology has been well documented, anti-IGF1R strategies are being tested clinically with antibodies and small molecule TKIs. Although anti-IGF1R antibody therapies have advanced into phase II and III clinical trials (Weroha and Haluska, 2008) , small molecule TKIs against both IGF1R and IR are just completing phase I clinical trials. To date, the TKIs have not shown specificity for IGF1R; significant inhibition of IR has also been observed with these compounds (Haluska et al., 2006; Ji et al., 2007) . This raises a very intriguing question: 'Is IR a valuable target in cancer cells, even though systemic inhibition may result in metabolic toxicity?' This study provides direct evidence that downregulation of IR alone inhibits cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis, suggesting that IR should also be targeted. At day 51, after whole-body imaging, mice were killed and lungs and livers were removed and placed into six-well plates. Ex vivo imaging is shown.
Insulin receptor affects cancer proliferation and metastasis H Zhang et al
Using a human phosphor-kinase profiler array, we show that in LCC6 cells, insulin stimulation resulted only in the phosphorylation of Akt at Ser 473. In the IR shRNA clone cells, the phosphorylation of Akt at this site was diminished after insulin treatment. Although we cannot rule out the possibility that other signaling pathways may be different between LCC6 and the IR shRNA clones at other time points of insulin treatment, our data imply that Akt phosphorylation and activation have a critical role in the proliferative and metastatic phenotype of LCC6 cells. These results are consistent with recent findings in transgenic mouse model systems showing a role for Akt2 in pulmonary metastasis (Dillon et al., 2009) . As new phosphatidylinositol 3-kinase and Akt inhibitors are developed, the importance of insulin stimulation of this pathway in metastasis should be clarified (Maira et al., 2008) . Downregulation of IR inhibited the anchorageindependent growth of both LCC6 and T47D cells. Furthermore, downregulation of IR in LCC6 cells inhibited xenograft tumor growth in athymic mice. All of these data show the important function of the IR in proliferation. These data are not surprising because insulin has been shown to stimulate cancer cell proliferation for over three decades (Osborne et al., 1976) . Other evidence also supports the idea that breast tumor growth is insulin dependent and IR downregulation affects tumor growth (Heuson and Legros, 1972; Novosyadlyy et al., 2009 ). Insulin does not interact with IGF1R or the IGF1R/IR hybrids at physiological concentrations ; thus, these effects are mainly mediated by IR. It is unknown whether one isoform or both isoforms of the insulin receptor have an important role in cell proliferation. The shRNA used in this study downregulated the level of both IR isoforms; thus, we are unable to attribute our results to a specific isoform. We and others have previously shown that IR-A, which binds insulin and IGF-II, is predominantly expressed in breast cancer specimens and breast cancer cell lines (Zhang et al., 2007) . Similarly, Avnet et al. (2009) have shown that IR-A is expressed more than IR-B in human osteosarcoma samples. These data imply that IR-A may have a more important role in tumor biology. Future studies dissecting the differences between these two isoforms are needed to shed further light on the subject. Furthermore, our data have shown that IR regulates angiogenesis and lymphangiogenesis of cancer cells. In the literature, VEGF-A produced by cancer cells has a significant role in angiogenesis and the metastatic dissemination of cancer cells. Our results have shown that the insulin receptor regulates VEGF-A transcription and expression, which is consistent with literature that IGF-I and insulin regulate VEGF-A through hypoxiainducible factor-1a in other types of cancer (Feldser et al., 1999; Fukuda et al., 2002; Treins et al., 2002; Stoeltzing et al., 2003; Li et al., 2006) . Although a few reports have shown that IGF-I regulates lymphangiogenesis (Tang et al., 2003; Bjorndahl et al., 2005) , we have failed to find literature regarding insulin and IR regulation of VEGF-D production and lymphangiogenesis in tumor cells. Therefore, our data suggest an important role of IR in lymphatic vessel formation in tumors.
Our data in LCC6 cells have shown that the IR, similar to IGF1R (Sachdev et al., 2004) , regulates metastasis in invasive cancer cells. Several molecular mechanisms mediated by IR may contribute to this phenotype. First, angiogenesis is essential to the metastatic dissemination of tumor cells to distant organs (Ademuyiwa and Miller, 2008) . Downregulation of IR in LCC6 cells significantly decreased the level of VEGF-A production, which may have contributed to both the reduced primary tumor proliferation at the mammary fat pad and the metastatic dissemination of tumor cells in the lung and liver of athymic mice. Second, lymphangiogenesis of IR shRNA xenograft tumors was reduced when compared with wild-type LCC6 xenografts. Lymphatic vessels are another pathway for tumor cells to disseminate (Eccles et al., 2007) . Third, through direct tail vein injection methods, we have shown that IR downregulation inhibits the colonization of LCC6 cells at distant sites including the lung and liver. This may be directly linked to the function of IR in cell survival and the ability to suppress anoikis. Finally, activation of IR signaling pathways might be required for colonization in specific host tissues. Although the most relevant mechanism is not certain, it is clear that IR function is necessary for spontaneous metastases.
Our studies have explored the function of IR in cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis. Yet, other aspects, such as tumor metabolism, have not been directly studied in these cells. Abnormalities in glucose metabolism (Warburg effect) is an increasingly 'rediscovered' hallmark of cancer (Vander Heiden et al., 2009) . It has been shown that IR has an important role in glucose metabolism of tumor cells . However, a substantial portion of glucose uptake is insulin independent (Zhang et al., 2007) and the direct effect of downregulation of IR on tumor metabolism needs further investigation.
As both IGF1R and IR have important functions in cancer biology, TKIs, which do not distinguish between the two receptors, might be more beneficial in treating cancer patients. Because of the concern of diabetic side effects with IR inhibition, TKIs might be used on an intermittent schedule or in combination with other conventional or targeted therapies. Moreover, a role for IR needs to be considered in the conduct of ongoing clinical trials. We believe that measurement of both IGF1R and IR in tumors will be needed to interpret the results of clinical trials. Although IGF1R is undoubtedly a target for cancer therapy, these data, along with those from other laboratories, suggest that IR may also be a target.
Materials and methods
Reagents
The reagents used in the study are described in Supplementary Materials and Methods.
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Cell lines and culture LCC6 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 11.25 nM human insulin, 50 units/ml penicillin and 50 mg/ml streptomycin. The origin of this cell line is controversial as it has features of both melanoma and breast cancer (Rae et al., 2007; Chambers, 2009) . T47D were cultured with Minimum Essential medium with 5% FBS, 6 ng/l human insulin, 1% of 100 Â non-essential amino acids, 50 units/ml penicillin and 50 mg/ml streptomycin. (Wang et al., 2006) . This vector was transiently transfected into the Pheonix Ampho cells (Orbigen, San Diego, CA, USA) to generate retroviral particles. Retroviral particles in the supernatant were used to infect LCC6 wild-type and IR shRNA cells. Cells were selected under regular culture media with 100 mg/ml of zeocin (Invitrogen, Carlsbad, CA, USA) for 3 days, and then cells were sorted by green fluorescent protein expression using flow cytometry. Green fluorescent protein-positive cells were cultured in Dulbecco's modified Eagle's medium with 10% FBS, 50 units/ml penicillin and 50 mg/ml streptomycin.
Flow cytometry
Wild-type cells and IR shRNA clones were incubated with a mouse immunoglobulin G control antibody, or an anti-human IR antibody (83-7) in phosphate-buffered saline (PBS)/1% bovine serum albumin/0.1% sodium azide (fluorescenceactivated cell sorting buffer) for 1 h at 4 1C. Cells were washed twice, and incubated with a goat anti-mouse antibody conjugated with allophycocyanin (Santa Cruz, Santa Cruz, CA, USA) for 30 min at 4 1C. Cells were washed twice, and resuspended with 400 ml fluorescence-activated cell sorting buffer. IR levels on cell surface were measured using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) with FL4 channel (661/16 nm bandpass).
Cell stimulation Cells were grown in regular growth media. Cells were washed twice with PBS and serum deprived for 24 h in serum-free media as described previously (Sachdev et al., 2004) . Medium was replaced with serum-free media containing IGF-I or insulin for times as indicated in figure legends.
Cell lysates
Cells were washed twice with ice-cold PBS on ice and lysed as previously described (Sachdev et al., 2003) . Protein concentration of cell lysates was determined using the bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL, USA).
Gel electrophoresis and immunoblotting
Gel electrophoresis and immunoblotting is shown in Supplementary Materials and Methods.
Human phosphor-kinase array LCC6 and IR shRNA clones cells were placed at 4 Â 10 6 cells per 10 cm dish. The next day, cells were starved in serum-free media. After 24 h, cells were treated with or without 20 nM insulin for 15 min. Cells were lysed and 300 mg of cellular lysates were used to perform the human phosphor-kinase array assay according to the manufacture's instruction (R&D Systems, Minneapolis, MN, USA).
Real-time reverse transcriptase-PCR assay Real-time reverse transcriptase-PCR assay is shown in Supplementary Materials and Methods.
VEGF-A enzyme-linked immunosorbent assay LCC6 and IR shRNA cells were plated in triplicate at 20 000 cells per well in 24-well tissue culture plates. Cells were treated in serum-free media, 2% FBS, 10% FBS or 2% FBS plus 100 mM of cobalt chloride for 48 h. The condition media was harvested and the level of VEGF in condition media was quantified using a VEGF enzyme-linked immunosorbent assay kit from R&D Systems.
Monolayer growth assay
Monolayer growth assay is shown in Supplementary Materials and Methods.
Anchorage-independent growth SeaPlaque-agarose (BioWhittaker, Walkersville, MD, USA), 1 ml of 0.8%, in culture medium was solidified in the bottom of each well of six-well plates. 1 Â 10 4 cells in growth media with 2% FBS were mixed in 0.45% agarose and overlaid on the bottom agar. After 9-10 days, colonies were counted under a microscope with a grid in the eyepiece. Five randomly selected fields were counted for each well, and the average total number of colonies from triplicate wells was shown.
Tumor growth in athymic mice
All animal studies were performed under the guidelines of the University-approved animal care and use protocol (Protocol no. 0511A77590 and renewed protocol no. 0807A40961). Female athymic mice (Foxn1nu strain from Harlan Sprague Dawley, Indianapolis, IN, USA), 4-5 weeks old, at five per group were injected in the second or seventh mammary fat pad with 5 Â 10 6 LCC6 cells. Tumor growth was measured twice each week. Tumor growth experiments were repeated three times. At the end of experiments, mice were killed and tumors were removed and fixed in formalin or frozen in optimal cutting temperature compound in liquid nitrogen. Formalinfixed tumor sections were stained with hematoxylin and eosin, Ki-67 or TUNEL, respectively, by the Neuropathology Laboratory in the Department of Laboratory Medicine and Pathology in University of Minnesota.
Tumor immunofluorescent staining
Tumor samples frozen in the optimal cutting temperature compound were sectioned at 6 mm thickness and acetone fixed. After blocking in 0.1% BSA and 3% donkey serum in PBS (Sigma, St Louis, MO, USA), tumor sections were incubated with goat anti-mouse lymphatic vessel endothelial hyaluronan receptor 1 antibody (1:100) for 30 min. After washing with PBS, sections were incubated with Cy2-conjugated AffiniPure donkey anti-goat immunoglobulin G (1:100) and rat antimouse phycoerythrin-CD31 (1:50) for 30 min. Finally, slides were briefly stained with 4,6-diamidino-2-phenylindole and were mounted with Prolong Gold antifade reagent.
Confocal microscopy
Confocal laser scanning microscopy was performed with an Olympus Fluoview FV500 laser scanning confocal system (Olympus, Walkersville, NY, USA) using an Â 20 oil immersion objective. Excitation lasers and filters were as follows: 4,6-diamidino-2-phenylindole, Blue Diode laser, emission 430-460 nm; Cy2-lymphatic vessel endothelial hyaluronan receptor 1, argon laser, emission 505-525 nm; and phycoerythrin-CD31, green He-Ne laser, emission LP 560 nm.
Analysis of lung micrometastasis
Mice carrying xenograft tumors were killed and lungs were fixed in formalin. Lung sections were stained with hematoxylin and eosin. Micrometastasis were counted through the wholelung section on slides using a microscope and quantified.
In vivo and ex vivo bioluminescent imaging 1 Â 10 6 LCC6 wild-type or IR shRNA clone cells were injected into the tail vein of the 4-to 5-week-old female athymic mice at five mice per group. In vivo bioluminescent imaging was performed at 3 h after the injection, and once a week afterward. In brief, mice were anesthetized with 3% isoflurane and injected retroorbitally with 100 ml of 30 mg/ml D-luciferin (Caliper Life Sciences, Hopkinton, MA, USA) in PBS. Bioluminescence images were acquired with the IVIS Imaging System (Xenogen, Hopkinton, MA, USA) at 2-5 min after injection. Analysis was performed using Living Image 2.5 software (Xenogen). For images taken at same day, the minimal and maximal counts were adjusted to be equal to reflect the difference among images. At the end point of study, five mice per group were imaged under 3% isofluranet. After imaging, mice were quickly killed and the lungs and livers were removed and put into six-well plates with 1 ml PBS for ex vivo imaging. Ex vivo bioluminescence images were acquired approximately 25-30 min after D-luciferin injection.
Statistical analysis
The statistical analysis is described in Supplementary Materials and Methods.
